Close Menu
Home › European Regulators Recommend Approval of Roche Treatment for HER2-Positive Breast Cancer

European Regulators Recommend Approval of Roche Treatment for HER2-Positive Breast Cancer

Nov 15, 2019
|
staff reporter

NEW YORK – Roche said on Friday that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended approval of its trastuzumab emtansine (Kadcyla) antibody-drug conjugate for the adjuvant treatment of adult patients with HER2-positive early breast cancer who have residual invasive disease, in the breast or lymph nodes, after neoadjuvant taxane-based and HER2-targeted therapy.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Dec
11
Featured Webinar

Advances in Precision Oncology: Tertiary Analysis Software for Solid Tumor NGS

This webinar will address how two molecular laboratories are implementing tertiary analysis software to improve their precision oncology workflows.

Dec
17
Featured Webinar

Non-Invasive Characterization of Solid Tumors via NGS Liquid Biopsy Testing

This webinar will review how liquid biopsy can be considered as an alternative and non-invasive method to tissue biopsy for cancer molecular characterization.

Dec
19
Featured Webinar

Evolution of Tumor Profiling in a Clinical Lab: Moving toward Comprehensive Genomic Profiling

Sponsored by
Qiagen

This webinar will provide a first-hand look at how a clinical lab evolved its tumor profiling workflow from a targeted panel approach toward comprehensive genomic profiling.  

Jan
28
Featured Webinar

Comprehensive Profiling of Myeloid Malignancies with Reliable Detection of FLT3 and CEBPA

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.  

What's Popular?

In Cancer

  1. Roche Ending Partnership With Syapse

  2. NCCN Updates Genetic Testing Guidelines for Assessing Breast, Ovarian, Pancreatic Cancer Risk

  3. Polygenic Modifiers of Pathogenic Genes May Refine Disease Risk Prediction

    Premium

  4. FDA Approves Foundation Medicine CDx for Novartis Breast Cancer Drug Piqray

  5. PGDx Gets IDE For Tissue NGS Test in Merck Immunotherapy Trial

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2019 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.